Vascular Biogenics (NASDAQ:VBLT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a research note published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research lowered Vascular Biogenics from a buy rating to a hold rating in a report on Friday, January 7th. Two investment […]

Related Keywords

,Vascular Biogenics Company Profile Get Rating ,Geode Capital Management ,Goldman Sachs Group Inc ,Zacks Investment Research ,Vascular Biogenics Ltd ,Spectrum Planning Advisory Services Inc ,Vascular Biogenics ,Get Rating ,Sachs Group ,Sigma Advisers ,Capital Management ,Advisory Services ,Jane Street Group ,Biogenics Company Profile ,Nasdaq Vblt ,Vblt ,Medical ,Initiated Coverage ,Stocknews Com ,